XADAGO is a type of prescription medicine known as monoamine oxidase type B (MAO-B) inhibitor used with levodopa and carbidopa to treat adults with Parkinson\u2019s disease (PD) who are having \u201coff\u201d episodes. It is not known if XADAGO is effective to treat PD when taken as a single medicine (monotherapy). It is not known if XADAGO is safe and effective in children. Active ingredient: safinamide mesylate Inactive ingredients: microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, hypromellose, polyethylene glycol 6000, iron oxide (red), potassium aluminum silicate, and titanium dioxide<\/p>\n
If safinamide tablets are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n
XADAGO (safinamide tablets) for oral use Initial U.S. Approval: 2017<\/p>\n","protected":false},"excerpt":{"rendered":"
XADAGO is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa\/carbidopa in patients with Parkinson\u2019s disease (PD) experiencing \u201coff\u201d episodes<\/p>\n
Approval Date: \u00a02017 If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201csafinamide tablets\u201d based on the information you provide.<\/strong><\/p>\n
\nProprietary Name: \u00a0XADAGO (safinamide) tablets
\nActive Ingredient(s): \u00a0safinamide
\nFDA-approved use:
\nDosage Form: \u00a0Tablets: 50 mg and 100 mg
\nMedicine Approved By: Food and Drug Administration (FDA)
\nManufacturer: US WorldMeds, LLC,
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n